---
layout: default
title: Cimicoxib
parent: 僅模型預測 (L5)
nav_order: 111
evidence_level: L5
indication_count: 0
---

# Cimicoxib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Cimicoxib: Drug Repurposing Evaluation — Insufficient Data for Prediction

## One-Sentence Summary

Cimicoxib (DB05095) is a selective COX-2 inhibitor originally developed for veterinary use (pain and inflammation management in dogs), with no approved human indications on record.
The TxGNN model returned **no predicted repurposing indications** for this drug, and the evidence pack contains **no clinical trials or publications** to support any new indication.
A full repurposing evaluation cannot be completed at this time; this report documents the current data state and recommended remediation steps.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Veterinary use (pain/inflammation in dogs; no human indication on record) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 (model returned no output; no supporting studies identified) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction is available for Cimicoxib in this evidence pack, so a formal mechanism-to-indication bridging analysis cannot be performed.

Cimicoxib is a selective cyclooxygenase-2 (COX-2) inhibitor belonging to the same pharmacological class as celecoxib and etoricoxib. In principle, selective COX-2 inhibition has a well-characterised mechanistic rationale across multiple human disease areas — including pain syndromes, inflammatory arthritis, and certain oncological indications — because COX-2-derived prostaglandins mediate inflammation, nociception, and tumour microenvironment signalling.

However, because the TxGNN knowledge-graph prediction pipeline returned an empty result set for this compound, no specific new indication can be evaluated at this stage. The absence of predictions may reflect limited DrugBank/knowledge-graph coverage for this veterinary compound, or may indicate that the drug's molecular profile does not produce statistically significant disease associations within the TxGNN model. Detailed mechanism of action data is not available in the current evidence pack, which further limits the assessment.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available in the evidence pack.

> **Note for analysts:** A manual PubMed search for "cimicoxib" retrieves primarily veterinary pharmacology publications. If a human repurposing hypothesis is to be developed (e.g., osteoarthritis, inflammatory pain), a targeted literature review against those specific indications should be commissioned separately.

---

## Denmark Market Information

Cimicoxib holds no marketing authorisations in Denmark (neither national Laegemiddelstyrelsen authorisations nor centralised EMA authorisations for human use). The compound is not currently marketed for human patients.

> **Note:** Cimicoxib is authorised in the EU under the trade name **Cimalgex** as a veterinary medicinal product (VMP) for dogs, regulated under the EMA's Committee for Medicinal Products for Veterinary Use (CVMP). This authorisation does not extend to human use.

---

## Safety Considerations

No human safety data (key warnings, contraindications, or drug–drug interactions) are available in the current evidence pack.

> Please refer to the approved Summary of Product Characteristics (SmPC) or the veterinary product literature for any available pharmacological safety information. Before any human repurposing programme is initiated, a dedicated human safety dossier must be compiled.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model returned no repurposing predictions for Cimicoxib, and the evidence pack contains no clinical, safety, or mechanistic data to support a specific new human indication. Proceeding without these foundations would not meet the minimum evidentiary threshold for a repurposing programme.

**To proceed, the following is needed:**

1. **Resolve TxGNN prediction gap** — Investigate why the model returned an empty prediction set. Confirm that DB05095 is correctly represented in the knowledge graph (node coverage, edge density). Re-run prediction after verifying DrugBank node inclusion.
2. **Obtain MOA data** — Query DrugBank API for DB05095 pharmacodynamics, mechanism, and targets. Populate `original_moa` to enable mechanism-based hypothesis generation.
3. **Establish a human repurposing hypothesis** — Given the COX-2 inhibitor class, candidate indications for manual evaluation include osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and colorectal cancer chemoprevention. A structured literature review (PubMed, Embase) should be performed.
4. **Compile human safety profile** — Retrieve any available phase I/II human pharmacokinetic or safety data. If none exist, a bridging toxicology assessment based on veterinary data and class-effect data from other COX-2 inhibitors will be required.
5. **Regulatory status check** — Confirm with Laegemiddelstyrelsen whether any compassionate use, named-patient, or investigational new drug (IND)-equivalent pathway is applicable for first-in-human studies in Denmark.
6. **Re-evaluate at next data cycle** — Once items 1–3 are resolved, resubmit to the TxGNN pipeline and generate an updated evidence pack before proceeding to a Go/Proceed with Guardrails decision.

---

*This report is generated for research purposes only. Findings do not constitute medical advice. Any drug repurposing candidate requires prospective clinical validation before therapeutic application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

